Try our Advanced Search for more refined results
In re Xyrem (Sodium Oxybate) Antitrust Litigation
Case Number:
3:20-md-02966
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Barnes & Thornburg
- Boies Schiller
- DiCello Levitt
- Edelson PC
- Fine Kaplan
- Gibson Dunn
- Girard Sharp
- Goodwin Procter
- Hagens Berman
- Holland & Knight
- Husch Blackwell
- Joseph Saveri Law Firm
- Kirkland & Ellis
- Labaton Keller
- Lowey Dannenberg
- Motley Rice
- O'Melveny & Myers
- Radice Law Firm
- Schneider Wallace
- Scott&Scott
- Skaggs Faucette
- Spector Roseman
- Spiro Harrison
- Steven Williams Law
- Troutman Pepper
- Westerman Law Corp.
- Wexler Boley
- White & Case
- Williams & Connolly
- Wilson Sonsini
- Zelle LLP
- Zimmerman Reed
Companies
- Aetna Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- Endo International PLC
- Express Scripts Holding Co.
- Florida Blue
- Government Employees Health Association Inc.
- Health Care Service Corp.
- Hikma Pharmaceuticals PLC
- Humana Inc.
- Jazz Pharmaceuticals Inc.
- Lupin Ltd.
- Mallinckrodt PLC
- Molina Healthcare Inc.
- Par Pharmaceutical Cos. Inc.
- Ranbaxy
- Teva Pharmaceutical Industries Ltd.
- United Food & Commercial Workers International Union
- West-Ward Pharmaceutical Corp.
- Wockhardt USA LLC
Sectors & Industries:
-
November 16, 2023
Illinois Seeks To Rejoin Narcolepsy Drug Overcharge Suit
Illinois is looking for a way back into an ongoing class action against Jazz Pharmaceuticals, telling the California federal judge presiding over the multidistrict case that another judge's order excluding Illinois insurers who reimbursed patients for the price of narcolepsy drug Xyrem should be reversed.
-
May 16, 2023
Jazz Ducks BCBS Claims But Not Xyrem Class Cert.
A California federal judge granted class certification Friday to insurers and consumers pursuing multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anti-competitive conduct and deals with other drugmakers, even as he nixed Blue Cross Blue Shield claims.